Sugi Predict

Sugi Predict / Targets / NOX5

NOX5

NADPH oxidase 5 · Q96PH1 · NOX5 on Sugi Atlas →

1,460 patent compounds predicted against NOX5, 979 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1459191 SCHEMBL1459191 1.00 20/20
SCHEMBL1459279 SCHEMBL1459279 1.00 20/20
SCHEMBL1460392 SCHEMBL1460392 1.00 20/20
SCHEMBL1565622 SCHEMBL1565622 1.00 20/20
SCHEMBL1565623 SCHEMBL1565623 1.00 20/20
SCHEMBL1565877 SCHEMBL1565877 1.00 20/20
SCHEMBL1565930 SCHEMBL1565930 1.00 20/20
SCHEMBL1566126 SCHEMBL1566126 1.00 20/20
SCHEMBL1566376 SCHEMBL1566376 1.00 20/20
SCHEMBL1566429 SCHEMBL1566429 1.00 20/20
SCHEMBL1566438 SCHEMBL1566438 1.00 20/20
SCHEMBL1566481 SCHEMBL1566481 1.00 20/20
SCHEMBL1566482 SCHEMBL1566482 1.00 20/20
SCHEMBL1566689 SCHEMBL1566689 1.00 20/20
SCHEMBL1566820 SCHEMBL1566820 1.00 20/20
SCHEMBL1567008 SCHEMBL1567008 1.00 20/20
SCHEMBL1566290 SCHEMBL1566290 0.74 20/20
SCHEMBL6880469 SCHEMBL6880469 1.00 19/20
SCHEMBL2217968 SCHEMBL2217968 0.56 16/20
SCHEMBL2216063 SCHEMBL2216063 0.59 12/20

Clinical trials — most relevant to NOX5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Neural Mechanism of Aldosterone-induced Insulin Resistance PHASE4WITHDRAWN
Cardiotoxicity in Breast Cancer Patients PHASE4RECRUITING
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE PHASE2UNKNOWN
Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing. PHASE1/PHASE2COMPLETED
Salt-Sensitivity and Immunity Cell Activation PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease PHASE1/PHASE2RECRUITING
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers PHASE1COMPLETED
NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM PHASE1WITHDRAWN
NOX-A12 First-in-human (FIH) Study PHASE1COMPLETED
Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation PHASE1WITHDRAWN
The Effect of Antioxidants on Skin Blood Flow During Local Heating PHASE1COMPLETED
Effect of IFN-γ on Innate Immune Cells PHASE1COMPLETED
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM EARLY_PHASE1RECRUITING
Endometriosis and Microvascular Dysfunction: Role of Inflammation EARLY_PHASE1RECRUITING
GSNOR Phenotyping/GSNO Challenge in Severe Asthma EARLY_PHASE1COMPLETED
Covid-19: Possible Role of Neutrophil Extracellular Traps nanUNKNOWN
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
Role of Nox2 in CNI-induced Renal Fibrosis nanCOMPLETED
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program) nanCOMPLETED
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19 nanCOMPLETED
Flow Mediated Dilation in Association With Hyperuricemia nanUNKNOWN
Effect Inhaled Nitric Oxide in Adult Liver Transplant nanNOT_YET_RECRUITING
Effects of Nitrate-rich Beetroot Juice in Pregnant Women With High Blood Pressure nanUNKNOWN
Mechanisms for Individual Differences in Hypertension in Obstructive Sleep nanCOMPLETED
Lung Mucus Hypersecretion and NQO1 nanCOMPLETED
Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis nanCOMPLETED
HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium nanCOMPLETED
Anti-inflammatory Effects of Fiber nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NOX5 binder may also engage these)

ProteinNameSimilarity
LPCAT1 Lysophosphatidylcholine acyltransferase 1 0.978 landscape →
NOX3 NADPH oxidase 3 0.978 landscape →
Q1HAQ0 — 0.976 Q1HAQ0 →
Q3TFD2 — 0.976 Q3TFD2 →
Q672K1 — 0.970 Q672K1 →
Q8JZN7 — 0.970 Q8JZN7 →
Q7TSA0 — 0.969 Q7TSA0 →
RHOT2 Mitochondrial Rho GTPase 2 0.967 landscape →
TRPM4 Transient receptor potential cation channel subfamily M member 4 0.966 landscape →
Q9ESQ5 — 0.966 Q9ESQ5 →
P52649 — 0.966 P52649 →
Q9D0Z3 — 0.965 Q9D0Z3 →
Q5R7A2 — 0.965 Q5R7A2 →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.965 landscape →
ALG1 Chitobiosyldiphosphodolichol beta-mannosyltransferase 0.965 landscape →
Q7TN37 — 0.965 Q7TN37 →
Q5E9M9 — 0.965 Q5E9M9 →
Q672J9 — 0.965 Q672J9 →
Q921Q3 — 0.964 Q921Q3 →
S5UH55 — 0.964 S5UH55 →
Q864R5 — 0.963 Q864R5 →
O97583 — 0.963 O97583 →
Q658P3 — 0.963 Q658P3 →
Q2TBP5 — 0.963 Q2TBP5 →
Q9JJH7 — 0.963 Q9JJH7 →
Q9UIX4 — 0.963 Q9UIX4 →
O89109 — 0.963 O89109 →
P51789 — 0.963 P51789 →
Q3TD49 — 0.963 Q3TD49 →
Q8CIZ9 — 0.963 Q8CIZ9 →